269 related articles for article (PubMed ID: 28019130)
1. Eliciting societal preferences of reimbursement decision criteria for anti cancer drugs in South Korea.
Kwon SH; Park SK; Byun JH; Lee EK
Expert Rev Pharmacoecon Outcomes Res; 2017 Aug; 17(4):411-419. PubMed ID: 28019130
[TBL] [Abstract][Full Text] [Related]
2. National reimbursement listing determinants of new cancer drugs: a retrospective analysis of 58 cancer treatment appraisals in 2007-2016 in South Korea.
Kim ES; Kim JA; Lee EK
Expert Rev Pharmacoecon Outcomes Res; 2017 Aug; 17(4):401-409. PubMed ID: 28010146
[TBL] [Abstract][Full Text] [Related]
3. Balancing costs and benefits at different stages of medical innovation: a systematic review of Multi-criteria decision analysis (MCDA).
Wahlster P; Goetghebeur M; Kriza C; Niederländer C; Kolominsky-Rabas P;
BMC Health Serv Res; 2015 Jul; 15():262. PubMed ID: 26152122
[TBL] [Abstract][Full Text] [Related]
4. A multi-criteria decision approach for ranking unmet needs in healthcare.
Cleemput I; Devriese S; Kohn L; Westhovens R
Health Policy; 2018 Aug; 122(8):878-884. PubMed ID: 29983193
[TBL] [Abstract][Full Text] [Related]
5. Dear policy maker: have you made up your mind? A discrete choice experiment among policy makers and other health professionals.
Koopmanschap MA; Stolk EA; Koolman X
Int J Technol Assess Health Care; 2010 Apr; 26(2):198-204. PubMed ID: 20392324
[TBL] [Abstract][Full Text] [Related]
6. A multi-stakeholder multicriteria decision analysis for the reimbursement of orphan drugs (FinMHU-MCDA study).
de Andrés-Nogales F; Cruz E; Calleja MÁ; Delgado O; Gorgas MQ; Espín J; Mestre-Ferrándiz J; Palau F; Ancochea A; Arce R; Domínguez-Hernández R; Casado MÁ;
Orphanet J Rare Dis; 2021 Apr; 16(1):186. PubMed ID: 33902672
[TBL] [Abstract][Full Text] [Related]
7. Integrating public preferences into national reimbursement decisions: a descriptive comparison of approaches in Belgium and New Zealand.
Leopold C; Lu CY; Wagner AK
BMC Health Serv Res; 2020 Apr; 20(1):351. PubMed ID: 32334579
[TBL] [Abstract][Full Text] [Related]
8. International experiences in multicriteria decision analysis (MCDA) for evaluating orphan drugs: a scoping review.
Lasalvia P; Prieto-Pinto L; Moreno M; Castrillón J; Romano G; Garzón-Orjuela N; Rosselli D
Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):409-420. PubMed ID: 31210065
[No Abstract] [Full Text] [Related]
9. Patient involvement in reflective multicriteria decision analysis to assist decision making in oncology.
Badia X; Aguarón A; Fernández A; Gimón A; Nafria B; Gaspar B; Guarga L; Gálvez M; Fuentes M; Paco N; Saldaña R
Int J Technol Assess Health Care; 2019 Jan; 35(1):56-63. PubMed ID: 30730288
[TBL] [Abstract][Full Text] [Related]
10. How to use multi-criteria decision analysis methods for reimbursement decision-making in healthcare: a step-by-step guide.
Diaby V; Goeree R
Expert Rev Pharmacoecon Outcomes Res; 2014 Feb; 14(1):81-99. PubMed ID: 24328890
[TBL] [Abstract][Full Text] [Related]
11. Decision-making criteria for medicine reimbursement in Slovenia: an expert panel discussion.
Detiček A; Janzic A; Locatelli I; Kos M
BMC Health Serv Res; 2018 Jun; 18(1):496. PubMed ID: 29945634
[TBL] [Abstract][Full Text] [Related]
12. Evidence and values: requirements for public reimbursement of drugs for rare diseases--a case study in oncology.
Drummond M; Evans B; LeLorier J; Karakiewicz P; Martin D; Tugwell P; MacLeod S
Can J Clin Pharmacol; 2009; 16(2):e273-81; discussion e282-4. PubMed ID: 19439771
[TBL] [Abstract][Full Text] [Related]
13. Stated and Revealed Preferences for Funding New High-Cost Cancer Drugs: A Critical Review of the Evidence from Patients, the Public and Payers.
MacLeod TE; Harris AH; Mahal A
Patient; 2016 Jun; 9(3):201-22. PubMed ID: 26370257
[TBL] [Abstract][Full Text] [Related]
14. Eight-year experience of using HTA in drug reimbursement: South Korea.
Bae EY; Hong JM; Kwon HY; Jang S; Lee HJ; Bae S; Yang BM
Health Policy; 2016 Jun; 120(6):612-20. PubMed ID: 27086557
[TBL] [Abstract][Full Text] [Related]
15. Are pricing and reimbursement decision-making criteria aligned with public preferences regarding allocation principles in the Polish healthcare sector?
Kolasa K
Expert Rev Pharmacoecon Outcomes Res; 2014 Oct; 14(5):751-62. PubMed ID: 25052370
[TBL] [Abstract][Full Text] [Related]
16. Making Good Decisions in Healthcare with Multi-Criteria Decision Analysis: The Use, Current Research and Future Development of MCDA.
Mühlbacher AC; Kaczynski A
Appl Health Econ Health Policy; 2016 Feb; 14(1):29-40. PubMed ID: 26519081
[TBL] [Abstract][Full Text] [Related]
17. Evaluation on the first 2 years of the positive list system in South Korea.
Park SE; Lim SH; Choi HW; Lee SM; Kim DW; Yim EY; Kim KH; Yi SY
Health Policy; 2012 Jan; 104(1):32-9. PubMed ID: 22001369
[TBL] [Abstract][Full Text] [Related]
18. Identifying and Revealing the Importance of Decision-Making Criteria for Health Technology Assessment: A Retrospective Analysis of Reimbursement Recommendations in Ireland.
Schmitz S; McCullagh L; Adams R; Barry M; Walsh C
Pharmacoeconomics; 2016 Sep; 34(9):925-37. PubMed ID: 27034245
[TBL] [Abstract][Full Text] [Related]
19. [Allocating resources for cancer control--resolving multicriteria decision-making using the analytic hierarchy process].
Gróf A
Magy Onkol; 2007; 51(3):197-208. PubMed ID: 17922059
[TBL] [Abstract][Full Text] [Related]
20. Societal views on NICE, cancer drugs fund and value-based pricing criteria for prioritising medicines: a cross-sectional survey of 4118 adults in Great Britain.
Linley WG; Hughes DA
Health Econ; 2013 Aug; 22(8):948-64. PubMed ID: 22961976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
